Galecto CEO departs; authorized shares increased to 500M; outstanding shares jump to 43.6M after preferred conversion

Damora Therapeutics, Inc.

CEO Hans T. Schambye departs effective Feb 10, 2026; COO Sherwin Sattarzadeh appointed interim principal executive officer.
Shareholders approve increase in authorized common shares from 300M to 500M, plus Cayman Islands redomestication.
Automatic conversion of Series C Preferred yields ~42M new shares; total outstanding rises from ~1.6M to ~43.6M.
Shareholders also approve 2026 Equity Incentive Plan and Employee Stock Purchase Plan.
Separation agreement for Schambye includes lump-sum base salary continuation, pro-rated bonus, and full equity acceleration.

item 5.02 item 5.03 item 5.07 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.95

Damora Therapeutics, Inc.: Certificate of Amendment to increase authorized shares of common stock from 300,000,000 to 500,000,000, effective upon filing on February 9, 2026 (effective 2026-02-09).

Change: charter amendment
Effective: 2026-02-09

Exact text from the filing

On February 9, 2026, in connection with the approval by stockholders of the Company at a special meeting of stockholders (the “Special Meeting”) as described in Item 5.07 below, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock, par value $0.00001 per share (“Common Stock”), from 300,000,000 to 500,000,000, which became effective upon filing.

View on SEC.gov

29 governance changes filed in the last 30 days. Browse all governance changes →

Damora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-043741

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.